Business
Oncolytics Biotech® Announces Closing of Public Offering of Units
Oncolytics Biotech® Announces Closing of Public Offering of Units Canada News...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Announces Closing of Public Offering of Units\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, June 1, 2017\n\n\n\n/THIS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/\n\n\n\nCALGARY, June 1, 2017 /CNW/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced the closing of its previously announced underwritten public offering. Oncolytics sold 16,445,000 units (Units) (including Units issued pursuant to the exercise in full of the over-allotment option granted by the Company to the underwriters) at a purchase price of $0.70 per Unit for gross proceeds of approximately $11.5 million (the Offering). The net proceeds of the Offering were approximately $10.6 million, after deducting the underwriting commissions and other estimated offering expenses payable by Oncolytics. Oncolytics expects to use the net proceeds from the Offering for, among other things, expanding partnering activities, execution of the clinical development program for metastatic breast cancer and general corporate purposes.\n\nCanaccord Genuity acted as sole bookrunner and sole lead for the Offering. Paradigm Capital Inc. acted as a manager for the Offering. \n\nA prospectus supplement and accompanying final base shelf prospectus describing the terms of the proposed offering has been filed on SEDAR. Copies of the prospectus supplement and accompanying final base shelf prospectus relating to the offering may be obtained from Canaccord Genuity, Attention: Syndication - Canaccord Genuity Corp., P.O. Box 516, 161 Bay Street, Suite 3000, Toronto, ON, M5J 2S1. Electronic copies of the prospectus supplement and accompanying final base shelf prospectus will also be available on SEDAR at www.sedar.com.\n\nThe securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the \"1933 Act) or any applicable securities laws of any state of the United States and may not be off...